BPC-157/TB-500/GHK-Cu/KPVAlso known as: Body Protection Compound (BPC-157), Thymosin Beta-4 (TB-500), Copper Peptide (GHK-Cu), Lysine-Proline-Valine (KPV), BTG-K Blend, B-T-G-K Blend

Mechanism of Action

The blend combines peptides with complementary mechanisms: BPC-157 promotes tissue repair via vascular endothelial growth factor (VEGF) modulation enhancing angiogenesis and healing; TB-500 facilitates cell migration and angiogenesis through actin cytoskeleton regulation; GHK-Cu stimulates collagen synthesis and exhibits antioxidant activity promoting skin regeneration; KPV modulates inflammation by inhibiting pro-inflammatory cytokines. Together, they synergistically promote tissue regeneration, collagen remodeling, and immune modulation in preclinical models.

Reported Research Benefits

Primarily used in preclinical and in vitro research for muscle regeneration, wound healing, skin rejuvenation, neuroprotection, inflammation reduction, tendon and ligament repair, and immune system modulation. The blend is also investigated for anti-aging potential and autoimmune disease models.

Dosing Protocol & Reconstitution

Supplied as lyophilized powder requiring reconstitution with bacteriostatic water. In research, doses vary but subcutaneous injection using insulin syringes is common, with concentration adjustments made based on experimental design. After reconstitution, storage is recommended at 2–8°C with a shelf-life up to 60 days.

Research Notes

Research shows potent regenerative effects including accelerated wound closure, enhanced angiogenesis, increased collagen deposition, and anti-inflammatory benefits. The blend has demonstrated synergy beyond individual peptides alone. Pharmacokinetics indicate moderate half-lives with effects observed in animal models for days post administration. Clinical data in humans is lacking.

Research Summary

An expanded healing blend adding KPV (Lys-Pro-Val), a potent anti-inflammatory tripeptide derived from α-MSH, to the BPC-157/TB-500/GHK-Cu stack. KPV directly inhibits NF-κB signaling in intestinal epithelial cells and immune cells, making this combination particularly targeted at gut inflammation and systemic recovery. Preclinical data supports its utility in IBD and injury recovery.

Side Effects & Safety

Adds KPV's generally favorable safety profile to the existing blend. KPV human data is limited to IBD research. No documented serious adverse events in animal models.

Stability & Storage

Refer to research notes

Molecular Data

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=BPC-157+KPV+anti-inflammatory+peptide